Pro-Dex Inc (PDEX) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Pro-Dex Inc stock $55.83, price $63.16, that is 11.6% below the price, quality 72 out of 100. Rating: overvalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range $13.16 – $73.41 · fair‑value band $29.93 – $83.17 · the $63.16 price screens above the $55.83 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 9, 2026.
Follow Pro-Dex in your weekly email
Every Wednesday you see whether Pro-Dex is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide.
Show moreShow less
It offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.
The company also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. Its products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations.
Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.
Stock analysis
Pro-Dex Inc (PDEX) currently trades at $63.16, while our model-based Fair Value estimate is $55.83, 12% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $84.51 per share, and 9 of the 24 models we run sit above the $63.16 price.
Bear case: the Asset-Based group reads lowest at $8.24, and 15 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: $29.93 (bear) to $83.17 (bull), the price of $63.16 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Pro-Dex Inc reported revenue of $77.5M in FY2026 versus $42.0M in FY2022, a compound +16.5%/yr. Reported net income was $13.7M in FY2026, compounding +31.5%/yr from FY2022.
Key figures
Market cap $210M Micro · P/E ratio 17.4 · P/S ratio 2.70 · EPS (TTM) $3.63 · Net margin 17.6% · Return on equity 32.4% · Return on assets (EBIT) 14.0% (5-year average) · Operating margin 17.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 72 out of 100 (medium confidence).
What moves the price
The share trades about 14% below its 52-week high and 118% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −12%, PDEX screens cheaper than that median.
Fair Value models
Bear$29.93Fair Value $55.83Bull$83.17
Price $63.16 · Downside -11.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 4 months old). Earnings retained since then ($1.31 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, 2 officers or directors sold shares worth $2.0M and none bought.
SaleRichard Lee Van Kirk JrChief Executive Officer, Director3× since May 21, 2026: 30,000 shares, avg. $61.23$1.8MSep 11, 202610b5-1 plan
SaleAlisha CharltonChief Financial Officer2,300 shares at $61.30$140,983Sep 9, 2026
SaleAngelita Rebamontan DomingoDirector998 shares at $47.24$47,146Mar 16, 2026
Plus 4 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.89/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+16.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
Start year 2021 (pandemic). Over 10 years: +14.4% a year
Revenue growth 39 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.9%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
+39.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year+39.6%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.27.7% vs 19.0%, picking up
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.12% → 17%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+22.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +19.7% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score72 · Top 25%
Fair Value upside−11.6% · Below median
Profitability
Return on equity (12 months)32.4% · Top 25%
Return on assets18.3% · Top 25%
Net margin (12 months)17.6% · Top 25%
Operating margin (12 months)17.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)16.6% · Above median
Balance sheet
Debt / equity0.28× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)17.4× · Cheaper than median
P/B4.40× · Priciest 25%
P/S (12 months)2.70× · Pricier than median
Price / free cash flow (fiscal year)31.0× · Pricier than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pro-Dex Inc Fair Value". https://www.fairvalue-calculator.com/stock/PDEX
Frequently asked questions
Is Pro-Dex Inc (PDEX) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of $55.83 versus a price of $63.16, about 12% lower (overvalued).
What is the fair value of PDEX?
Our model-based fair value for Pro-Dex Inc is $55.83 (as of Nov 9, 2026), built from audited fundamentals. The current price: $63.16.
What is the quality score of PDEX?
Pro-Dex Inc has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pro-Dex Inc (PDEX)?
Our model-based price target is the fair value of $55.83 (as of Nov 9, 2026) from 24 valuation models. Cautious scenario $29.93, optimistic scenario $83.17. It is a calculation from audited fundamentals, not an analyst target.
What is the Pro-Dex Inc stock forecast for 2026?
Our models put fair value at $55.83, about 12% lower versus a price of $63.16 (overvalued). Cautious scenario $29.93, optimistic scenario $83.17. The calculation is refreshed regularly with new filings.
What is the revenue of Pro-Dex Inc (PDEX)?
Pro-Dex Inc reported trailing-twelve-month revenue of about $77.5M (latest available figure, as of Nov 9, 2026).
What growth is priced into Pro-Dex Inc (PDEX)?
For today's price to be fair in a discounted-cash-flow model, Pro-Dex Inc would have to grow free cash flow by +22.5 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +13.0 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of PDEX use?
Our models discount Pro-Dex Inc at 11.2 %: a base by market capitalisation (micro), damped by beta 0.04, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pro-Dex Inc that is +22.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Pro-Dex Inc (PDEX) delivered so far?
Over the past 5 years revenue at Pro-Dex Inc grew +13.0 % a year. The price currently implies free-cash-flow growth of +22.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pro-Dex Inc (PDEX) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Pro-Dex Inc (+22.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pro-Dex Inc (PDEX)?
The free-cash-flow yield on the price is 3.23 %: that much free cash flow Pro-Dex Inc produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pro-Dex Inc (PDEX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pro-Dex Inc it is $55.83 per share (as of Nov 9, 2026), against a price of $63.16. It is the blended result of 24 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Pro-Dex Inc stock overvalued or undervalued in 2026?
As of Nov 9, 2026, PDEX trades above its calculated fair value: price $63.16, fair value $55.83, a gap of about −12% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PDEX?
No. The price is what the market pays today ($63.16); the fair value is what the company's own numbers justify ($55.83). For Pro-Dex Inc the two are $7.33 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pro-Dex Inc worth?
The market values Pro-Dex Inc at about $210M (market capitalisation, as of Nov 9, 2026). Per share that is $63.16; our models calculate a fair value of $55.83 per share.
What do the bullish and bearish scenarios say about PDEX?
Our models span a range for Pro-Dex Inc: cautious scenario $29.93, base $55.83, optimistic $83.17 per share (as of Nov 9, 2026, price $63.16). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PDEX?
Pro-Dex Inc trades at a price-to-earnings ratio of 17.4 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $55.83 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings, 8 of the years ex one-offs: 13.8. Other multiples: P/B 4.4, P/S 2.7, EV/EBITDA 14.9.
How solid is the balance sheet of Pro-Dex Inc (PDEX)?
Balance-sheet figures for Pro-Dex Inc (as of Nov 9, 2026): return on equity 32.4%, debt of 0.28 per unit of equity. They feed the Quality Score of 72/100, which measures business quality independently of the share price.
How far is PDEX from its 52-week high?
Pro-Dex Inc trades at $63.16, about 14% below its 52-week high of $73.41 and 118% above the low of $28.91 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $55.83 is for.
Which stocks are comparable to Pro-Dex Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pro-Dex Inc stock attractive at the current price?
The data as of Nov 9, 2026: price $63.16, calculated fair value $55.83 (−12%), Quality Score 72/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PDEX calculated?
We run Pro-Dex Inc through 24 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of $55.83 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Pro-Dex Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pro-Dex Inc (PDEX)?
The closing price on Nov 6, 2026 was $63.16. Our model-based fair value is $55.83, about 12% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pro-Dex Inc right now?
The model range is unusually wide ($29.93 to $83.17). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Pro-Dex Inc
How large is the market capitalisation of Pro-Dex Inc (PDEX)?
The market capitalisation of Pro-Dex Inc is $210M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pro-Dex Inc (PDEX)?
The price-to-sales ratio of Pro-Dex Inc is 2.70 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pro-Dex Inc (PDEX)?
Earnings per share at Pro-Dex Inc are $3.63 (price ÷ EPS = P/E 17.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Pro-Dex Inc (PDEX)?
The net margin of Pro-Dex Inc is 17.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pro-Dex Inc (PDEX)?
The return on equity (ROE) of Pro-Dex Inc is 32.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pro-Dex Inc (PDEX)?
On an EBIT basis the return on assets of Pro-Dex Inc is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pro-Dex Inc (PDEX)?
The operating margin of Pro-Dex Inc is 17.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pro-Dex Inc (PDEX)?
Revenue at Pro-Dex Inc is growing +16.6% versus a year earlier (3y avg +18.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pro-Dex Inc (PDEX)?
Earnings per share at Pro-Dex Inc are growing +143% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Pro-Dex Inc (PDEX) carry?
The net debt of Pro-Dex Inc is $9.9M (fiscal year 2026, ≈ 1.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pro-Dex Inc in the live analysis
One click puts Pro-Dex Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026